Paper Details

  1. Home
  2. Paper Details

26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.

Author: Bencomo-AlvarezAlfonso E, EiringAnna M, GonzalezMayra A, LaraJoshua J, RubioAndres J, VelazquezVanessa V, YoungJames E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the potential of PSMD1 and PSMD3, 19S regulatory components of the 26S proteasome, as novel targets for cancer therapy. Analysis of data from TCGA and CPTAC databases revealed a correlation between the expression of these proteins and overall survival in various cancers. These findings suggest that targeting PSMD1 and PSMD3 may be a promising strategy for cancer prognosis and treatment.
Paper Details　
Original Abstract of the Article :
Ever since the ubiquitin proteasome system was characterized, efforts have been made to manipulate its function to abrogate the progression of cancer. As a result, the anti-cancer drugs bortezomib, carfilzomib, and ixazomib targeting the 26S proteasome were developed to treat multiple myeloma, mantl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472613/

データ提供：米国国立医学図書館（NLM）

Targeting the Proteasome: New Hope for Cancer Therapy

Cancer, like a relentless sandstorm, can engulf the body, destroying healthy cells and tissues. This study delves into the complex world of the ubiquitin proteasome system (UPS), a cellular machinery that regulates protein degradation and plays a crucial role in cancer development.

Exploring the Proteasome's Role in Cancer

The researchers investigated the potential of targeting the 26S proteasome, a key component of the UPS, as a therapeutic strategy for cancer. This is akin to finding a weakness in the sandstorm's structure, allowing us to control and potentially break its destructive force. The study revealed that targeting specific non-ATPase subunits of the proteasome, such as PSMD1 and PSMD3, could induce apoptosis (programmed cell death) in cancerous cells, suggesting their potential as novel drug targets.

Potential for Personalized Cancer Treatment

The study's findings offer exciting possibilities for developing new and targeted therapies for cancer, potentially improving treatment outcomes and minimizing side effects. This is like discovering a rare oasis with a unique set of resources, allowing us to tailor our approach to treating specific types of cancer based on their unique characteristics.

Dr. Camel's Conclusion

The study highlights the potential of targeting the proteasome as a therapeutic strategy for cancer. Further research is needed to explore the specific roles of PSMD1 and PSMD3 in different cancers, but this study offers valuable insights into the complex mechanisms of the UPS and its potential as a target for personalized cancer therapies.
Date :
  1. Date Completed 2021-11-22
  2. Date Revised 2023-09-21
Further Info :

Pubmed ID

34572038

DOI: Digital Object Identifier

PMC8472613

Related Literature

Article Analysis
・Effects of ixazomib・Side Effects of ixazomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.